Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)
Clinically meaningful achievement of primary and secondary endpoints is first major advance in treatment of low-grade glioma in more than
Read More